2seventy bio, Inc. (TSVT) Stock Analysis

2seventy bio, Inc. (TSVT) Healthcare & Pipeline Overview

2seventy bio, Inc. is a U.S.-based biotechnology company pioneering cell and gene therapies for cancer, with a specialized focus on CAR-T cell therapeutics for multiple myeloma. Its pipeline features idecabtagene vicleucel (Abecma) and bb21217, underpinned by a strategic partnership with Bristol-Myers Squibb, positioning it within the innovative oncology treatment landscape.

What Is the Investment Thesis for TSVT?

2seventy bio, Inc. presents a research profile centered on its innovative CAR-T cell therapies for multiple myeloma, a high-growth segment within oncology. The company's key value drivers include the commercialized idecabtagene vicleucel (Abecma) and the clinical-stage candidate bb21217, both targeting a challenging hematologic malignancy with persistent unmet needs. The strategic partnership with Bristol-Myers Squibb Company provides a robust framework for development and commercialization, offering shared resources and expertise crucial for navigating the complex biotechnology landscape. Financially, the company operates with a market capitalization of $266M and a gross margin of 45.9%, reflecting its specialized product and operational focus. However, a significant profit margin of -73.6% underscores the substantial investment in research and development and the inherent high costs associated with advanced drug development and regulatory processes. Key growth catalysts include potential label expansions or increased market penetration for Abecma, successful clinical progression and regulatory approval of bb21217, and further strategic collaborations. Risks involve the high costs and regulatory hurdles common to biotech firms, potential adverse clinical trial outcomes, and intense competition within the CAR-T therapy market. Investors monitor clinical trial results, regulatory decisions, and the evolving competitive landscape.

Based on FMP financials and quantitative analysis

TSVT Key Highlights

Market capitalization stands at $0.27 billion, reflecting its current valuation within the specialized biotechnology sector.

• Reports a negative profit margin of -73.6%, indicative of significant investment in research and development and early-stage commercialization typical for biotech firms.
• Achieved a gross margin of 45.9%, demonstrating efficiency in the production or licensing of its specialized therapeutic candidates.
• Operates with a Beta of 1.05, suggesting a volatility profile slightly higher than the broader market.
• Maintains a focused operational structure with 65 employees, supporting its specialized cell and gene therapy development efforts.

Who Are TSVT's Competitors?

TSVT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TSVT's Key Strengths?

Innovative CAR-T cell therapy technology with a focused pipeline for multiple myeloma.

• Commercialized product, idecabtagene vicleucel (Abecma), providing market presence and revenue.
• Strategic partnership with Bristol-Myers Squibb Company, offering significant resources and support.
• Specialized focus on a high-need area within oncology, addressing critical unmet medical needs.

What Are TSVT's Weaknesses?

Significant negative profit margin (-73.6%) indicative of high R&D costs and early commercialization phase.

• Reliance on a limited number of pipeline candidates, primarily for a single disease indication.
• High regulatory hurdles and complex manufacturing requirements inherent to cell and gene therapies.
• Small employee base (65 employees) potentially limiting internal resource scalability compared to larger pharmaceutical firms.

What Could Drive TSVT Stock Higher?

TSVT catalyst: Commercial expansion and increased adoption of idecabtagene vicleucel (Abecma) in the U.S. market for multiple myeloma, driven by continued physician education and patient access initiatives.

• Potential regulatory updates or approvals for bb21217, should it successfully complete ongoing clinical trials and demonstrate a favorable risk-benefit profile, opening new commercialization avenues.
• Further clinical trial data readouts for bb21217, which could provide additional evidence of efficacy and safety, influencing its development pathway and market potential.
• Strategic developments or expanded collaborations stemming from the partnership with Bristol-Myers Squibb Company, potentially leading to new joint ventures or accelerated pipeline progress.

What Are the Key Risks for TSVT?

Financial-distress signal — its Altman Z-Score of -0.97 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-24.6%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Significant research and development costs associated with cell and gene therapy development, contributing to the negative profit margin of -73.6% and requiring substantial ongoing capital investment.
• Adverse clinical trial outcomes or regulatory setbacks for its pipeline candidates, particularly bb21217, which could significantly impact future commercialization prospects and company valuation.
• Intense competitive landscape within the CAR-T cell therapy market, with numerous companies developing similar or next-generation therapies, potentially limiting market share and pricing power.
• Stringent regulatory hurdles and complex manufacturing requirements inherent in the development and commercialization of advanced cell and gene therapies, leading to delays or increased costs.
• Dependence on the strategic partnership with Bristol-Myers Squibb Company for certain aspects of development and commercialization, introducing partnership-related risks such as changes in strategic priorities or disagreements.

What Are the Growth Opportunities for TSVT?

• Commercial Expansion of Idecabtagene Vicleucel (Abecma): As a commercialized CAR-T cell therapy for multiple myeloma, Abecma represents a significant current revenue stream. Growth opportunities lie in increasing its market penetration and adoption among eligible patients within the U.S. market. This involves continued engagement with oncology specialists and treatment centers to ensure awareness and access. The persistent unmet need for effective treatments in relapsed or refractory multiple myeloma patients provides a substantial patient pool, and further clinical data or real-world evidence could support broader utilization, driving revenue growth for 2seventy bio.
• Advancement of bb21217 through Clinical Development: The successful progression of bb21217, another CAR-T cell therapeutic candidate for multiple myeloma, through its clinical development stages is a critical growth driver. Positive clinical trial results demonstrating efficacy and safety could lead to regulatory approval and subsequent commercialization. Introducing a second CAR-T product for multiple myeloma could expand the company's market share, potentially offering differentiated benefits or targeting different patient populations within the disease spectrum, thereby diversifying its product portfolio and revenue streams.
• Leveraging Strategic Partnership with Bristol-Myers Squibb: The existing strategic partnership with Bristol-Myers Squibb Company is a vital asset. This collaboration provides 2seventy bio with access to significant resources, including funding, research capabilities, manufacturing expertise, and potentially broader commercial infrastructure. Deepening or expanding the scope of this partnership, or initiating new collaborative projects, could accelerate the development of pipeline candidates, enhance manufacturing efficiencies, or facilitate market access, thereby de-risking development and accelerating the path to market for future therapies.
• Innovation in CAR-T Cell Therapy Platform: Continuous innovation and optimization of 2seventy bio's core CAR-T cell therapy platform represent a long-term growth opportunity. Advancements in cell engineering, manufacturing processes, or the development of next-generation CAR-T constructs with improved efficacy, safety profiles, or broader applicability could strengthen the company's competitive position. Such technological leadership could lead to new intellectual property, potential licensing opportunities, and the ability to address an even wider range of cancers or patient populations beyond its current multiple myeloma focus.
• Addressing Unmet Needs in Multiple Myeloma Treatment: Multiple myeloma remains a challenging and incurable cancer, with patients often experiencing relapse and requiring continuous treatment innovation. 2seventy bio's dedicated focus on this disease allows it to capitalize on the ongoing demand for novel, highly effective therapies. By developing and commercializing advanced CAR-T cell treatments, the company directly addresses these critical unmet needs, positioning itself as a key player in improving patient outcomes and capturing market share in a segment where conventional treatments may have limited long-term efficacy.

What Are TSVT's Competitive Advantages?

• Proprietary cell and gene therapy platforms, specifically in CAR-T cell development, which represent complex and highly specialized biotechnological expertise and intellectual property.
• Established commercialized product, idecabtagene vicleucel (Abecma), providing a significant market presence and clinical validation in specific multiple myeloma treatment lines.
• Strategic partnership with Bristol-Myers Squibb Company, offering shared resources, development capabilities, and potentially broader market reach and manufacturing scale that smaller biotechs might lack.
• Deep scientific expertise and specialized focus on CAR-T candidates for multiple myeloma, creating high barriers to entry for potential competitors in this niche.

What Does TSVT Do?

Founded in 2021 and headquartered in Cambridge, Massachusetts, 2seventy bio, Inc. operates as a biotechnology firm dedicated to advancing the field of cell and gene therapies for cancer. The company's core mission is to discover, develop, and commercialize innovative treatments specifically within the U.S. market, addressing significant unmet needs in oncology. Its strategic focus lies in Chimeric Antigen Receptor (CAR-T) cell therapies, which represent a cutting-edge approach to immunotherapy where a patient's own T-cells are engineered to recognize and attack cancer cells. A cornerstone of 2seventy bio's pipeline is idecabtagene vicleucel, commercially known as ide-cel or Abecma. This CAR-T cell therapeutic candidate is specifically designed to treat multiple myeloma, a complex and often relapsing hematologic malignancy. Abecma has achieved commercialization, providing a tangible revenue stream and validating the company's scientific capabilities in bringing advanced therapies to market. Complementing Abecma, 2seventy bio is also developing bb21217, another CAR-T cell therapeutic candidate aimed at further enhancing treatment options for multiple myeloma patients. The company's development efforts are significantly bolstered by a strategic partnership with Bristol-Myers Squibb Company, a collaboration that provides access to broader resources, expertise, and potentially expanded commercialization capabilities. This partnership is crucial for navigating the high costs and intricate regulatory pathways inherent in cell and gene therapy development. With a focused team of 65 employees, 2seventy bio maintains a specialized operational structure, concentrating its efforts on its defined therapeutic areas and leveraging its innovative technology to address critical challenges in cancer treatment.

What Products and Services Does TSVT Offer?

• Develops advanced cell and gene therapies specifically for cancer treatment.
• Specializes in Chimeric Antigen Receptor (CAR-T) cell therapeutics, a form of immunotherapy.
• Focuses on treating multiple myeloma, a type of blood cancer, within the U.S. market.
• Markets idecabtagene vicleucel, known as ide-cel or Abecma, for multiple myeloma.
• Is actively developing bb21217, another CAR-T cell candidate for multiple myeloma.
• Engages in discovery, development, and commercialization activities for its therapeutic pipeline.
• Maintains a strategic partnership with Bristol-Myers Squibb Company for collaborative efforts.
• Aims to bring innovative and transformative cancer treatments to patients in need.

How Does TSVT Make Money?

• Generates revenue from the commercial sales of its approved cell and gene therapy, idecabtagene vicleucel (Abecma), for multiple myeloma in the U.S. market.
• Receives payments, which may include research funding, milestone payments, and potential royalties, from its strategic partnership with Bristol-Myers Squibb Company for collaborative development and commercialization efforts.
• Invests heavily in the research and development of new CAR-T cell therapeutic candidates, with the aim of securing future regulatory approvals and commercialization opportunities.
• Seeks to expand the market reach and indications for its existing and pipeline products through clinical trials and regulatory filings.

What Industry Does TSVT Operate In?

2seventy bio, Inc. operates within the highly dynamic and innovation-driven biotechnology industry, a sub-sector of healthcare focused on developing novel biological products and processes. The company specifically targets the cell and gene therapy market, a rapidly expanding segment within oncology that is characterized by substantial research and development investment and significant potential for transformative treatments. This market is driven by advancements in genetic engineering and immunology, offering new hope for diseases previously considered untreatable. 2seventy bio's focus on CAR-T cell therapies for multiple myeloma positions it in a competitive yet high-demand niche. The competitive landscape includes both established pharmaceutical giants and other specialized biotech firms developing similar or alternative advanced therapies for cancer. Success in this industry hinges on robust clinical trial outcomes, navigating complex regulatory pathways, and effective commercialization strategies. The company's innovative technology and strategic partnership are critical differentiators in this evolving and capital-intensive environment.

Who Are TSVT's Key Customers?

• Oncology specialists and hematologists who prescribe advanced cell and gene therapies for patients with multiple myeloma.
• Hospitals and specialized treatment centers equipped with the infrastructure and expertise to administer complex CAR-T cell therapies.
• Patients diagnosed with multiple myeloma, particularly those who have relapsed or are refractory to prior treatments, seeking innovative therapeutic options.
• Healthcare systems and insurance payers that cover the costs associated with high-value, specialized cell and gene therapies.

Return on equity for 2seventy bio, Inc. stands at -24.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -11.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -32.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.67 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -21.9%, the inverse of the P/E and a quick read on earnings relative to price.

2seventy bio, Inc. (TSVT) Valuation Context

Valued at $266M, TSVT is classified as a micro-cap stock.

Company Profile

2seventy bio, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO William D. Baird III,. TSVT has traded publicly since 2021.

2seventy bio, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.97 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project 2seventy bio, Inc. revenue of about $75.1M for fiscal 2026, with EPS near $-0.15. The estimate reflects 3 contributing analysts.

TSVT Financials

TSVT Latest News

No recent news available for TSVT.

2seventy bio, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources